combination therapies Archives

Oncotarget News

Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

March 27, 2024

this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”BUFFALO, NY- March 27, 2024 – A new research paper was... read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”BUFFALO, NY- March 25, 2024 – A new... read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,... read more

Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality

Oncotarget

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

March 6, 2024

We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.”BUFFALO,... read more

Figure 2: Immunoblot assessment of effects on cell-cycle, pro- and anti-apoptosis signaling events mediated by Sacituzumab govitecan plus platinum-based chemotherapeutics in human TNBC, SCLC, and UBC tumor-lines.

Oncotarget

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

March 4, 2024

these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”BUFFALO, NY- March 4, 2024 – A new research paper... read more

Figure 7: Combined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02

Oncotarget

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells

February 26, 2024

The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell... read more

Figure 1: Combined targeting of SMO and BRD4 as a potential therapeutic strategy against melanoma.

Oncotarget

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

July 19, 2023

This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors.”BUFFALO, NY- July 19,... read more

Figure 7: Immunological effect of Nerofe and DOX: CT26 murine model showing the immunological effect of Nerofe, DOX, and their combined treatment.

Oncotarget

Transformation of Immunosuppressive mtKRAS Tumors Into Immunostimulatory Tumors by Nerofe and Doxorubicin

July 5, 2023

we demonstrated that the combination of Nerofe and DOX exerts a synergistic effect during mCRC treatment [...]”BUFFALO, NY- July 5, 2023 – A new research paper was published in Oncotarget's Volume... read more